Zai Lab (ZLAB) Net Income towards Common Stockholders (2018 - 2026)
Zai Lab (ZLAB) posted quarterly Net Income towards Common Stockholders of -$51.0 million for Q1 2026, down 5.32% year-on-year from -$53.9 million in Q1 2025, and down 1.2% on a QoQ basis from -$50.4 million in Q4 2025.
Zai Lab (ZLAB) Net Income towards Common Stockholders (2018 - 2026) Analysis & Trends
Zai Lab (ZLAB) has reported Net Income towards Common Stockholders for 9 consecutive years, with -$51.0 million the latest figure, recorded in Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 5.32% year-over-year to -$51.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$178.1 million (up 29.34% YoY) and the FY2025 annual result came in at -$175.5 million, up 31.73% from the prior year.
- Net Income towards Common Stockholders declined to -$51.0 million in Q1 2026 per ZLAB's latest filing, from -$50.4 million in the prior quarter.
- Over the last five years, Net Income towards Common Stockholders for ZLAB reached as high as -$36.0 million in Q3 2025 and fell as low as -$161.2 million in Q3 2022.
- A 5-year average of -$74.2 million and a median of -$61.8 million in 2022 frame the typical range for Net Income towards Common Stockholders.
- The largest YoY upside for Net Income towards Common Stockholders was 70.84% in 2022 against a maximum downside of 67.19% in 2022.
- Year by year, Net Income towards Common Stockholders stood at -$61.8 million in 2022, then sank by 54.49% to -$95.4 million in 2023, then advanced by 14.4% to -$81.7 million in 2024, then surged by 38.29% to -$50.4 million in 2025, then decreased by 1.2% to -$51.0 million in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$51.0 million, -$50.4 million, and -$36.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,380.63 Bn | 66,380.34 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,910.39 Bn | 1,910.33 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 470.95 Bn | 466.16 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.97 Bn | 114.72 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.92 Bn | 61.16 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - | -0.68 |
| 8 | Argenx Se | 55.76 Bn | 50.58 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Zai Lab | 20.61 Bn | 19.86 Bn | 61.30 Mn | -51.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -51.02 Mn |
| Dec 31, 2025 | -50.41 Mn |
| Sep 30, 2025 | -35.96 Mn |
| Jun 30, 2025 | -40.73 Mn |
| Mar 31, 2025 | -48.44 Mn |
| Dec 31, 2024 | -81.68 Mn |
| Sep 30, 2024 | -41.67 Mn |
| Jun 30, 2024 | -80.28 Mn |
| Mar 31, 2024 | -53.47 Mn |
| Dec 31, 2023 | -95.43 Mn |
| Sep 30, 2023 | -69.15 Mn |
| Jun 30, 2023 | -120.90 Mn |
| Mar 31, 2023 | -49.14 Mn |
| Dec 31, 2022 | -61.77 Mn |
| Sep 30, 2022 | -161.19 Mn |
| Jun 30, 2022 | -137.93 Mn |
| Mar 31, 2022 | -82.39 Mn |
| Dec 31, 2021 | -211.83 Mn |
| Sep 30, 2021 | -96.41 Mn |
| Jun 30, 2021 | -163.32 Mn |